Prof Sherene Loi
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
797 Scholarly works
42 Projects
HIGHLIGHTS
2026
Journal article
Analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge
DOI: 10.1038/s41467-026-72956-x2026
Journal article
Germline BRCA1 pathogenic variants and T cell dysfunction
DOI: 10.1016/j.iotech.2026.1016012026
Research grants (ARC, NHMRC, MRFF)
Innovating in Breast Cancer Immunology Treatment and Prevention
2022
Journal article
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice.
DOI: 10.1038/s43018-022-00413-x2021
Journal article
Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
DOI: 10.1093/jnci/djab1112018
Research Grant
Capture: Circulating Tumour Dna Assessment of Pik3ca to Guide Treatment Response
2018
Research grants (other domestic)
2018 NBCF Endowed Chair Program
RECENT SCHOLARLY WORKS
2026
Journal article
Antibody–drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation
DOI: 10.1016/j.esmoop.2026.1083162026
Journal article
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial.
DOI: 10.1093/jnci/djag0952026
Journal article
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
DOI: 10.1016/j.annonc.2026.04.0112026
Journal article
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
DOI: 10.1038/s41467-026-75660-y2026
Journal article
Clarifying risk-factor associations with quantitative breast tumor features: a pooled analysis of 24 studies.
DOI: 10.1093/jnci/djag2442026
Journal article
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.
DOI: 10.1038/s41523-026-00971-82026
Journal article
Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1 metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.
DOI: 10.1200/jco.2026.44.17_suppl.lba10002026
Journal article
Giredestrant (GIRE) palbociclib (PALBO) vs letrozole (LET) PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER , HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial.
DOI: 10.1200/jco.2026.44.17_suppl.lba1006